Xenetic Biosciences XBIO 深 沪
已收盘 10-23 16:00:00 美东时间
1.72
-0.210
-10.88%
华盛通- 最 高1.9002
- 今 开1.90
- 成交量 2.21万股
- 最 低 1.72
- 昨 收 1.93
- 总市值 403.03万
- 52周最高 4.9392
- 市盈率 静 --
- 换手率 0.94%
- 52周最低 1.72
- 委 比 -96.08%
- 总股本 234.32万
- 历史最高 1074.00
- 量 比 1.71
- 振 幅 9.34%
- 历史最低 1.72
- 每 手 1
- 风险率 0.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Xenetic Biosciences Announces Its Collaboration Partner PeriNess Doses First Participant In Clinical Trial Of Systemic Recombinant Human DNase To Treat Large B-Cell Lymphoma In Israel
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has informed the Company t...
10-15 20:49
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition
Xenetic Biosciences Inc. (NASDAQ:XBIO) on Wednesday struck a definitive share exchange agreement to purchase Santersus AG, a privately held therapeutic medical device firm advancing its selective blood purification platform. The all-stock deal hinges on shareholder approval and involves exchanging n...
09-16 22:28
Xenetic Biosciences Q2 EPS $(0.41) Up From $(0.45) YoY, Sales $660.601K Up From $589.897K YoY
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.41) per share. This is a 8.89 percent increase over losses of $(0.45) per share from the same period last year. The company reported $660.601 thousand in sales this quarter. This is a 11.99 percent increase over sales of $589.897 tho...
08-07 21:28
Xenetic Biosciences Reports ASCO 2026 Data Showing DNase I Boosts CAR-T Expansion And Anti-Tumor Activity In B-Cell Cancer Models
New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignanciesData highlight potential of DNase I to improve CAR-T cell
06-01 21:06
Xenetic Biosciences reports Q1 results
Xenetic Biosciences press release (XBIO): Q1 net loss decreased approximately 49% to approximately $0.5 million, compared to approximately $0.9 million for the same period in 2025. Royalty revenue inc...
05-13 20:26
Xenetic Biosciences Q1 EPS $(0.20) Up From $(0.59) YoY, Sales $806.923K Up From $593.261K YoY
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.20) per share. This is a 66.1 percent increase over losses of $(0.59) per share from the same period last year. The company reported $806.923 thousand
05-13 05:27
Xenetic Biosciences Grants Equity Award to Interim CEO
An announcement from Xenetic Biosciences ( ($XBIO) ) is now available. On April...
04-25 06:16
Xenetic Biosciences reports FY results
Xenetic Biosciences press release (XBIO): FY Net loss for the year ended December 31, 2025 was approximately $2.7 million, reflecting investment in the Company's most promising scientific programs. R...
03-14 03:26
Xenetic Biosciences Q4 EPS $(0.22) Beats $(0.52) Estimate, Sales $766.296K Beat $690.000K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.52) by 57.69 percent. This is a 67.65 percent increase over losses of $(0.68) per share
03-13 20:11
Xenetic Biosciences faces ongoing delays in annual meeting
An update from Xenetic Biosciences ( ($XBIO) ) is now available. On December 11...
01-10 06:15
